The case for & against
Bull & Bear analysis
Globus Medical, Inc. (NYSE: GMED) is a leading player in the musculoskeletal technology sector focused on spinal and orthopedic solutions. The company specializes in innovative surgical products designed to improve patient outcomes, with a strong emphasis on developing cutting-edge technology in spinal surgery. Recent acquisitions, such as NuVasive and Nevro, position Globus Medical favorably for capturing growth opportunities amid rising demand for advanced musculoskeletal care. This aligns with the ongoing shift towards more minimally invasive surgical techniques and robotics in healthcare.
Bull says
- ↑Q1 revenue rose 27% YoY to $759.9M, led by U.S. spine sales
- ↑Launched over 30 products since NuVasive deal, expanding interbody portfolio
- ↑FY2026 guidance set at $3.18–3.22B revenue and $4.70–$4.80 EPS
- ↑Gross margin improved to 69.2%, reflecting operational efficiencies
- ↑High earnings yield and strong liquidity support financial flexibility
- ↑$390M remaining share buyback underscores institutional confidence
Bear says
- ↓Ongoing Nevro integration presents revenue volatility and execution risk
- ↓Recent downgrades cite decelerating revenue momentum and mixed outlook
- ↓Rising SG&A pressures threaten operating margin and profitability
- ↓Weak profitability and revisions factors signal subdued earnings outlook
- ↓Heavy reliance on U.S. spine exposes business to market downturns
- ↓Low momentum factors may deter investors and weight share performance
Investment themes with GMED
Robotics and automation technology companies
Devices and instruments for medical treatment
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Overall, we are moving with purpose and in the right direction. As we progress through 2026, look for market share taking top line growth, coupled with exciting product launches, while increasing gross margins and driving meaningful earnings expansion.
- Since then, revenue has more than tripled. We've generated six times the amount of free cash flow, all while closing two significant deals, extinguishing almost $1 billion in debt, while deploying over $600 million to repurchase over 10 million shares at an average price of under $60 a share.
- Q1 revenue totaled $759.9 million growing 27% as reported and 25.5% on a constant currency basis.
Bear points
- we also saw a decline in revenue, driven by the structural changes made within sales and marketing of the Nevro business at the tail end of 2025.